Eledon Pharmaceuticals, Inc. — Director's Dealing 2025

Jan 13, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eledon Pharmaceuticals, Inc. (ELDN)
CIK: 0001404281
Period of Report: 2025-01-10

Reporting Person: McBride John S. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-10	Stock Option (right to buy)	$4.04	A	30870	Acquired	2035-01-10	Common Stock (30870)	Direct
2025-01-10	Restricted Stock Units	$	A	3430	Acquired		Common Stock (3430)	Direct

Footnotes

F1: This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026.

F2: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.

F3: 100% of the total restricted stock units will vest on January 10, 2026.